The present invention provides novel compositions for suppressing or improving hair loss, and compositions for suppressing or improving graying. More specifically, it provides agents that stabilize type XVII collagen expression, preferably agents that suppress the degradation of type XVII collagen by ELANE inhibitors and such, and compositions comprising a DNA repair-promoting agent or a DNA damage-suppressing agent as an active ingredient. Advantageous suppressive effects of hair loss and graying can be obtained when a composition comprising as an active ingredient a suppressive agent of type XVII collagen degradation such as an ELANE inhibitor is administered to a mammal. For the ELANE inhibitors, suppressive agents of type XVII collagen degradation and DNA repair-promoting agents, low-molecular compounds, polypeptides, proteins, antibodies, or nucleic acid medicine such as antisense oligos or siRNAs may be used. A method of screening for effective substances for suppression of hair loss and graying is also provided.

A method of treating a skin condition resulting from exposure to pollution or free radicals is disclosed. The method can include topically applying to skin having the skin condition a composition comprising an effective amount of an extract of Diospyros mespiliformis leaf to reduce oxidative damage in the skin having the skin condition.

A method of treating a skin condition resulting from exposure to pollution or free radicals is disclosed. The method can include topically applying to skin having the skin condition a composition comprising an effective amount of an extract of Diospyros mespiliformis leaf to reduce oxidative damage in the skin having the skin condition.

Disclosed is a powder composition consisting essentially of Magnolia officinalis bark extract comprising magnolol and honokiol, tocopherol or tocopherol acetate, lecithin, at least one gum, and optionally water, wherein the composition is in powdered form.

Disclosed is a powder composition consisting essentially of Magnolia officinalis bark extract comprising magnolol and honokiol, tocopherol or tocopherol acetate, lecithin, at least one gum, and optionally water, wherein the composition is in powdered form.

The present invention relates to an aqueous composition for ophthalmological use or otolaryngological use, the aqueous composition containing: (A) a petrolatum; and two or more (B) nonionic surfactants.

The present invention relates to an aqueous composition for ophthalmological use or otolaryngological use, the aqueous composition containing: (A) a petrolatum; and two or more (B) nonionic surfactants.

The present invention relates to a formulation that can be utilised to facilitate expression of natural behaviour in pigs, and in particular sows and weaners and a method which utilises the formulation for the same.

The present invention relates to a formulation that can be utilised to facilitate expression of natural behaviour in pigs, and in particular sows and weaners and a method which utilises the formulation for the same.

A steam therapy equipment including a vessel for heating a mixture of water and organic materials, a compressor to inject pressurized air into the vessel producing pressurized steam. The pressurized steam is conducted into the equipment via one or more valves. The therapy equipment is formed from at least one panel and may include a supporting frame. The therapy equipment includes a temperature sensor to measure the temperature inside the therapy equipment when pressurized steam is admitted via the valves. A patient enters the equipment and is exposed to the pressurized steam, causing dilation of the skin pores of the patient, whereby toxins are removed from the patient. One or more applicators may conduct pressurized steam to specific portions of the body of the patient. The patient may be provided with a portion of the mixture to consume as part of the steam therapy treatment.